Search Results - "Callaghan, T J"

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Codeine Therapy in the Context of Cytochrome P450 2D6 (CYP2D6) Genotype by Crews, K R, Gaedigk, A, Dunnenberger, H M, Klein, T E, Shen, D D, Callaghan, J T, Kharasch, E D, Skaar, T C

“…Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine as an…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for Cytochrome P450 2D6 Genotype and Codeine Therapy: 2014 Update by Crews, K R, Gaedigk, A, Dunnenberger, H M, Leeder, J S, Klein, T E, Caudle, K E, Haidar, C E, Shen, D D, Callaghan, J T, Sadhasivam, S, Prows, C A, Kharasch, E D, Skaar, T C

“…Codeine is bioactivated to morphine, a strong opioid agonist, by the hepatic cytochrome P450 2D6 (CYP2D6); hence, the efficacy and safety of codeine are…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing by Caudle, K E, Rettie, A E, Whirl-Carrillo, M, Smith, L H, Mintzer, S, Lee, M T M, Klein, T E, Callaghan, J T

“…Phenytoin is a widely used antiepileptic drug with a narrow therapeutic index and large interpatient variability, partly due to genetic variations in the gene…”
Get full text

Clinical Pharmacogenetics Implementation Consortium Guidelines for Human Leukocyte Antigen-B Genotype and Allopurinol Dosing by Hershfield, M S, Callaghan, J T, Tassaneeyakul, W, Mushiroda, T, Thorn, C F, Klein, T E, Lee, M T M

“…Allopurinol is the most commonly used drug for the treatment of hyperuricemia and gout. However, allopurinol is also one of the most common causes of severe…”
Get full text

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update by Saito, Y, Stamp, LK, Caudle, KE, Hershfield, MS, McDonagh, EM, Callaghan, JT, Tassaneeyakul, W, Mushiroda, T, Kamatani, N, Goldspiel, BR, Phillips, EJ, Klein, TE, Lee, MTM

“…The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA‐B*58:01 Genotype and Allopurinol Dosing was originally published in February…”
Get full text

Implementation of a pharmacogenomics consult service to support the INGENIOUS trial by Eadon, MT, Desta, Z, Levy, KD, Decker, BS, Pierson, RC, Pratt, VM, Callaghan, JT, Rosenman, MB, Carpenter, JS, Holmes, AM, McDonald, CA, Benson, EA, Patil, AS, Vuppalanchi, R, Gufford, BT, Dave, N, Robarge, JD, Hyder, MA, Haas, DM, Kreutz, RP, Dexter, PR, Skaar, TC, Flockhart, DA

“…Hospital systems increasingly utilize pharmacogenomic testing to inform clinical prescribing. Successful implementation efforts have been modeled at many…”
Get full text

Confidence interval criteria for assessment of dose proportionality by SMITH, Brian P, VANDENHENDE, Francois R, DESANTE, Karl A, FARID, Nagy A, WELCH, Pamela A, CALLAGHAN, John T, FORGUE, S. Thomas

“…The aim of this work was a pragmatic, statistically sound and clinically relevant approach to dose-proportionality analyses that is compatible with common…”
Get full text

Olanzapine : pharmacokinetic and pharmacodynamic profile by CALLAGHAN, J. T, BERGSTROM, R. F, PTAK, L. R, BEASLEY, C. M

“…Multicentre trials in patients with schizophrenia confirm that olanzapine is a novel antipsychotic agent with broad efficacy, eliciting a response in both the…”
Get full text

The physical properties and response of osteoblasts to solution cast films of PLGA doped polycaprolactone by Tang, Z.G., Callaghan, J.T., Hunt, J.A.

“…Polycaprolactone films doped with poly(lactide-co-glycolide) (65:35) in 0, 10, 20, and 30 (wt%) were prepared and evaluated in terms of morphology, dynamic…”
Get full text

QT Effects of Duloxetine at Supratherapeutic Doses: A Placebo and Positive Controlled Study by Zhang, Lu, Chappell, Jill, Gonzales, Celedon R, Small, David, Knadler, Mary P, Callaghan, JT, Francis, Jennie L, Desaiah, Durisala, Leibowitz, Mark, Ereshefsky, Larry, Hoelscher, David, Leese, Philip T, Derby, Michael

“…BACKGROUND:The electrophysiological effects of duloxetine at supratherapeutic exposures were evaluated to ensure compliance with regulatory criteria and to…”
Get full text

Disposition and Biotransformation of the Antipsychotic Agent Olanzapine in Humans by Kelem Kassahun, Edward Mattiuz, Eldon Nyhart, Jr, Boyd Obermeyer, Todd Gillespie, Anthony Murphy, R. Michael Goodwin, David Tupper, J. Thomas Callaghan, Louis Lemberger

“…Disposition and biotransformation of the new antipsychotic agent olanzapine (OLZ) were studied in six male healthy volunteers after a single oral dose of 12.5…”
Get full text

The Effects of Supratherapeutic Doses of Duloxetine on Blood Pressure and Pulse Rate by Derby, Michael A, Zhang, Lu, Chappell, Jill C, Gonzales, Celedon R, Callaghan, J T, Leibowitz, Mark, Ereshefsky, Larry, Hoelscher, David, Leese, Philip T, Mitchell, Malcolm I

“…The effects of supratherapeutic dosages of duloxetine, a serotonin and norepinephrine reuptake inhibitor, on blood pressure and pulse rate were assessed in a…”
Get full text

THE CONDUCT OF IN VITRO AND IN VIVO DRUG-DRUG INTERACTION STUDIES: A PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PhRMA) PERSPECTIVE by BJORNSSON, Thorir D, CALLAGHAN, John T, KUMAR, Gondi, MCLEOD, James, OBACH, R. Scott, ROBERTS, Stanley, ROE, Amy, SHAH, Anita, SNIKERIS, Fred, SULLIVAN, John T, TWEEDIE, Donald, VEGA, Jose M, EINOLF, Heidi J, WALSH, John, WRIGHTON, Steven A, FISCHER, Volker, GAN, Lawrence, GRIMM, Scott, KAO, John, KING, S. Peter, MIWA, Gerald, LAN NI

“…Current regulatory guidances do not address specific study designs for in vitro and in vivo drug-drug interaction studies. There is a common desire by…”
Get full text

Olanzapine: Interaction Study with Imipramine by Callaghan, John T., Cerimele, Benito J., Kassahun, Kelem J., Nyhart Jr, Eldon H., Hoyes-Beehler, Pamela J., Kondraske, George V.

“…Olanzapine is an “atypical” antipsychotic agent with a high affinity for serotonin 5HT2A/C, 5HT3, 5HT6, and dopamine D1, D2, D3, D4 receptors. Depressed…”
Get full text

The design and production of Co–Cr alloy implants with controlled surface topography by CAD–CAM method and their effects on osseointegration by Hunt, John Alan, Callaghan, Jill T., Sutcliffe, Chris J., Morgan, Rhys H., Halford, Ben, Black, Richard A.

“…Improved fixation and increased longevity are still important performance criteria in the development of orthopaedic prostheses. The osseointegration of a…”
Get full text

Lack of Effect of Olanzapine on the Pharmacokinetics of a Single Aminophylline Dose in Healthy Men by Macias, William L., Bergstrom, Richard E, Cerimele, Benito J., Kassahun, Kelem, Tatum, David E., Callaghan, John T.

“…Study Objective. To test whether olanzapine, an atypical antipsychotic, is an inhibitor of cytochrome P450 (CYP) 1A2 activity, we conducted a drug interaction…”
Get full text

Nizatidine, an H2-blocker. Its metabolism and disposition in man by Knadler, M P, Bergstrom, R F, Callaghan, J T, Rubin, A

“…The disposition of a single oral dose of about 150 mg of nizatidine, an H2-blocker, was studied in five men. Plasma levels of both parent drug and…”
Get more information

Role of serum prolactin determination in evaluation of impotent patient by Foster, R S, Mulcahy, J J, Callaghan, J T, Crabtree, R, Brashear, D

“…Hyperprolactinemia is a recognized cause of impotence. The discovery of elevated prolactin levels in impotent men is very important since pharmacotherapy in…”
Get more information

Disposition in humans of racemic picenadol, an opioid analgesic by Franz, P M, Anliker, S L, Callaghan, J T, DeSante, K A, Dhahir, P H, Nelson, R L, Rubin, A

“…Racemic picenadol is being tested clinically as an analgesic. The (+)-enantiomer of picenadol is an opioid agonist and the (-)-enantiomer is a weak…”
Get more information

Secretion of nizatidine into human breast milk after single and multiple doses by Obermeyer, B D, Bergstrom, R F, Callaghan, J T, Knadler, M P, Golichowski, A, Rubin, A

“…Disposition of the H2-receptor antagonist nizatidine was studied in serum, urine, and breast milk. Five lactating women and five nonlactating women…”
Get more information